TLSA Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (21 geg. 2024 @ 23:00):

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology...

Stats
Šios dienos apimtis	120 371
Vidutinė apimtis	198 846
Rinkos kapitalizacija	84.53M
EPS	$0 ( 2024-04-22 )
Kita pelno data	( $0 ) 2024-05-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.82
ATR14	$0.00800 (0.98%)

Tūris Koreliacija

Ilgas: 0.09 (neutral)

Trumpas: 0.28 (neutral)

Signal:(59.974) Neutral

Tiziana Life Sciences PLC Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos
FITBP	-0.876
ACGLN	-0.87
PFF	-0.853
ENLV	-0.842
RCEL	-0.838
JSM	-0.837
ADSK	-0.827
FITBO	-0.814
FTXH	-0.811
BJK	-0.806

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Tiziana Life Sciences PLC Koreliacija - Valiuta/Žaliavos

0.14
( neutral )

0.35
( neutral )

0.00
( neutral )

0.52
( weak )

0.69
( moderate )

-0.47
( neutral )

Tiziana Life Sciences PLC Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$-51 000.00 (0.00 %)
EPS:	$-0.160

FY	2022
Pajamos:	$0
Bruto pelnas:	$-51 000.00 (0.00 %)
EPS:	$-0.160

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.139

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.120

Financial Reports:

No articles found.

Tiziana Life Sciences PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Tiziana Life Sciences PLC

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.

Realaus laiko atnaujinimai Tiziana Life Sciences PLC [TLSA]

Upcoming Earnings Alert

Tiziana Life Sciences PLC Options Data

Calls

Puts